Search
Eplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalregulatory feedback of aldosterone on renin secretion. … Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative
Products: INSPRA 50MG, EPLERENHEXAL 50MGMefloquine
go.drugbank.com/drugs/DB00358ApprovedMalaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. … It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche.
Dichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269Approved[A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical. … [L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773]
Follitropin
go.drugbank.com/drugs/DB00066ApprovedInvestigationalHowever, these small differences do not affect the bioactivity compared to natural FSH. … Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility.
Products: Gonal-f RFF Pen, REKOVELLE 12mcg/0.36mL solution for Injection in pre-filled penVibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016. … Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors.
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Benzhydrocodone
go.drugbank.com/drugs/DB15465Approved[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]
Latamoxef
go.drugbank.com/drugs/DB04570ApprovedLatamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins
Polythiazide
go.drugbank.com/drugs/DB01324Approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p826)